Kovtoniuk D. M.

CALCIUM ANTAGONIST AMLODIPINE AND PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES (LITERATURE REVIEW)

---

Show/Download

About the author:

Kovtoniuk D. M.

Heading:

LITERATURE REVIEWS

Type of article:

Scientific article

Annotation:

This literature review is a scientific search for the prescription of calcium antagonists (CA) in arterial hypertension (AH) and the combination of AH and various forms of coronary heart disease (CHD), which allows the practitioner to use drugs of this group in patients of different risk categories considering pharmacotherapeutic features and to pay attention to issues that require further study, considering possible complications and adverse reactions (AR) when using drugs of this group. The publication aims to provide a practitioner with an answer to the appropriateness of using CA amlodipine in a particular clinical situation. The results of the literature analysis from the PubMed, BioMed Central, and Free Medical Journals databases for 2016-2023 were used. Most of the literature reviewed in the course of writing this review did not contain comparative characteristics of the potential clinical use of CA, so the review discusses possible options for using these drugs and draws conclusions about their feasibility. A comprehensive systematic literature search was conducted to identify clinical trials relevant to the review topic. The author reviewed the search results to identify relevant studies and assessed the results to minimize bias. The author could not review individual participant data, as this data is not publicly available according to the study protocols. However, it is worth noting that analyzing the data of each individual participant is more informative for studying the results of treatment and may affect the analysis and further tactics of use. Thus, the issue of prescribing amlodipine from the calcium antagonist group in specific clinical situations was discussed in patients with chronic heart failure and patients with coronary heart disease. Further study of the drugs in this group will allow doctors to use them without endangering the lives of patients.

Tags:

Bibliography:

1. Brunström M, Carlberg B. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018 Jan 1;178(1):28-36. DOI: 10.1001/jamainternmed.2017.6015.
2. World health organization. World health statistics 2019: monitoring health for the SDGs, sustainable development goals. WHO; 2019. 132 p. Available from: https://www.who.int/publications-detailredirect/9789241565707.
3. National Center for Health Statistics (US). Health, United States, 2019. Hyattsville (MD): National Center for Health Statistics (US); 2021. DOI: 10.15620/cdc:100685.
4. Diachuk DD, Moroz HZ, Hidzynska, TS. Poshyrenist faktoriv ryzyku sertsevo-sudynnykh zakhvoriuvan v Ukraini: suchasnyi pohliad na problemu. Ukrainskyi kardiolohichnyi zhurnal 2018;1:91-101. Dostupno: . [in Ukrainian].
5. Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J Am Coll Card. 2019;74(20):2529-2532. DOI: 10.1016/j.jacc.2019.10.009.
6. Canoy D, Rahimi K. Blood pressure-lowering treatment lowers mortality and cardiovascular disease risk, but whether effects differ at an arbitrary threshold of 140 mm Hg systolic blood pressure requires further research. BMJ Evid Based Med. 2018 Oct;23(5):189-190. DOI: 10.1136/bmjebm-2018-110934.
7. Choi KH, Park MS, Kim JT, Kim HS, Kim JH, Nam TS, et al. Lipoic acid use and functional outcomes after thrombolysis in patients with acute ischemic stroke and diabetes. PLoS ONE. 2016;(11):e0163484 DOI: 10.1371/journal. pone.0163484.
8. Toyo-Oka T, Nayler W. Third generation calcium entry blockers. Blood Pres. 2018;5(4):2018-2019. DOI: 10.3109/08037059609079672.
9. Swartz RH, Bayley M, Lanctôt KL, Murray BJ, Cayley ML, Lien K, et al . Post-stroke depression, obstructive sleep apnea, and cognitive impairment: Rationale for, and barriers to, routine screening. Int J Str. 2016;11:509-518. DOI: 10.1177/1747493016641968.
10. Watts RW, Wing LM. A placebo–controlled comparison of diltiazem and amlodipine monotherapy in essentional hypertension using 24–h ambulatory monitoring. Blood Press. 2018;7(1):25-30. DOI: 10.1080/080370598437538.
11. Kranenburg G, Spiering W, de Jong PA, Kappelle LJ, de Borst GJ, Cramer MJ, et al. Inter-arm systolic blood pressure differences, relations with future vascular events and mortality in patients with and without manifest vascular disease. Int J Cardiol. 2017 Oct 1;244:271-276. DOI: 10.1016/j.ijcard. 2017.06.044.
12. Horwitz LD, Weinberger HD, Clegg L. Comparison of amlodipine and long–acting diltiazem in the treatment of mild or moderate hypertension. Am J Hypertension. 2018;10(11):1263-1269. DOI: 10.1016/s0895-7061(97)00264-1.
13. Ajayi AA, Akintomide AO. The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension . J of N M Ass. 2017;87(7):485-488.
14. Ferrucci A, Marcheselli А, Strano S, Ciavarella G, Messa F, Calcagnini G. 24–hour blood pressure profiles in patients with hypertension treated with amlodipine or nifedipine GITS. Cll Drug Invest. 2017;13(1):67-72. DOI: 0000-0003-2832-2020.
15. Nold G, Strobel G, Lemmer B. Morning versus evening amlodipine treatment: Effect of circadian blood pressure profile in essential hypertensive patients. Blood Pres Mon. 2018;3(1):17-25. Available from: .
16. Leenen FH, Fourney A, Notman G, Tanner J. Persistence of antihypertensive effect after missed doses of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half–life. British J Clin Pharm. 2018;41(2):83-88. DOI: 10.1111/j.1365-2125.1996.tb00164.x.
17. Hayduk K, Adamczak M, Nowitzki G. Is initial dose titration of amlodipine worthwhile in patients with mild to moderate hypertension? Cur Med R and Op. 2015;15(1):39-45. DOI: 10.1185/03007999909115172.
18. Lichtlen PR, Fisher LD. Analysis of arrhythmias in the Circadian Antiischemia Program in Europe (CAPE) study. J Card Pharm. 2020;33(1):135-139. DOI: 10.1097/00005344-199901000-00020.
19. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RHJr, Neaton JD, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional–hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circul. 2019;91:98-706. DOI: 10.1161/01.cir.91.3.698.
20. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2016;363:2022-2031. DOI: 10.1016/S0140- 6736(04)16451-9.
21. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circ. 2000;102:1503-10. DOI: 10.1161/01.cir.102.13.1503.
22. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J Am Med Assoc. 2004;292:2217-26. DOI: 10.1001/jama. 292.18.2217.
23. Jørgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES). J Amer Coll of Card. 2002;35:592-99. DOI: 10.1016/s0735-1097(99)00599-9.
24. Xie W, Zheng F, Evangelou E, Liu O, Yang Z, Chan Q, et al. Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis. J Hypertens. 2018 Jun;36(6):1256-1265. DOI: 10.1097/HJH.0000000000001720.
25. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. DOI: 10.1097/HJH.0000000000003480.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 1, 172, 44-54 pages, index UDC 615.221:616.11/.14-085

DOI:

10.29254/2077-4214-2024-1-172-44-54